Latham & Watkins Advises the Lead Placement Agent in Unum Therapeutics’ Private Placement in connection with its Acquisition of Kiq LLC

Unum Therapeutics Inc., a biopharmaceutical company focused on developing therapies for solid tumors, has announced it has completed the acquisition of Kiq LLC, a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors. Concurrent with the acquisition of Kiq, Unum entered into a definitive agreement for the sale of Series A non-voting convertible Preferred Stock in a private placement to a group of institutional accredited investors led by Fairmount Funds Management LLC, with participation from Venrock Healthcare Capital Partners, BVF Partners L.P., Atlas Venture, Acorn Bioventures, Perceptive Advisor's LLC, RTW Investments, OrbiMed, Samsara BioCapital, Logos Capital, Ally Bridge Group and Commodore Capital, as well as additional undisclosed institutional investors. The private placement is expected to result in gross proceeds to Unum of approximately $104.4 million before deducting placement agent and other offering expenses. 

Latham & Watkins LLP represents Jefferies LLC, the lead placement agent for the private placement, in the transaction with a New York-based team led by partner Nathan Ajiashvili, with associates Roger Yarett and Victoria McGrath.